6+ hour, 10+ min ago  (688+ words) Neurocrine Biosciences, forever a possible M&A target in the biopharma industry, is making a major acquisition itself. Neurocine has reached a deal to acquire Soleno Therapeutics for $2.9 billion, bagging recently FDA-approved Vykat XR (diazoxide choline), the first therapy for…...